Lyell Immunopharma Inc (LYEL)

May 14, 2025

Lyell Immunopharma: Q1 Earnings Snapshot - The Washington Post

May 14, 2025

May 14, 2025

Lyell Immunopharma Advances CAR T-Cell Therapy Pipeline - TipRanks

May 14, 2025

May 13, 2025

Lyell Immunopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025

May 13, 2025

Lyell Immunopharma Reports Clinical Progress and Financial Results for LYL314 CAR T-Cell Therapy Targeting Relapsed/Refractory Large B-Cell Lymphoma - Nasdaq

May 13, 2025

May 13, 2025

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 - GlobeNewswire

May 13, 2025

May 13, 2025

Breakthrough Lymphoma Treatment: Lyell's Dual-Target Therapy Achieves 94% Response Rate in Clinical Trial - Stock Titan

May 13, 2025

May 03, 2025

Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Monday - Defense World

May 03, 2025

May 03, 2025

JPMorgan Chase & Co. Buys 336,516 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

May 03, 2025

May 01, 2025

LYEL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com

May 01, 2025

May 01, 2025

Lyell Immunopharma Announces Oral Presentation of New - GlobeNewswire

May 01, 2025

May 01, 2025

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025 - Stock Titan

May 01, 2025

May 01, 2025

Renaissance Technologies LLC Purchases 1,414,746 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

May 01, 2025

May 01, 2025

Lyell Immunopharma Inc [LYEL] Records 200-Day SMA of $0.9472 - knoxdaily.com

May 01, 2025

Apr 29, 2025

Geode Capital Management LLC Raises Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

Apr 29, 2025

Apr 28, 2025

Financial Metrics Check: Lyell Immunopharma Inc (LYEL)’s Ratios for Trailing Twelve Months - DWinneX

Apr 28, 2025

Apr 24, 2025

A better buy-in window may exist right now for Lyell Immunopharma Inc (LYEL) - Sete News

Apr 24, 2025

Apr 24, 2025

Lyell Immunopharma Inc [LYEL] Director makes an insider purchase of 35,640 shares worth 19958.0. - knoxdaily.com

Apr 24, 2025

Apr 22, 2025

Can you now get a good deal on Lyell Immunopharma Inc’s shares? - uspostnews.com

Apr 22, 2025

Apr 19, 2025

Lyell Immunopharma’s (LYEL) Neutral Rating Reiterated at HC Wainwright - Defense World

Apr 19, 2025

Apr 19, 2025

Lyell Immunopharma (NASDAQ:LYEL) Receives “Neutral” Rating from HC Wainwright - The AM Reporter

Apr 19, 2025

Apr 15, 2025

FDA grants RMAT status to Lyell’s lymphoma therapy By Investing.com - Investing.com South Africa

Apr 15, 2025

Apr 15, 2025

Lyell Immunopharma gets FDA RMAT status for lymphoma treatment - Seeking Alpha

Apr 15, 2025

Apr 15, 2025

FDA grants RMAT status to Lyell’s lymphoma therapy - Investing.com

Apr 15, 2025

Apr 15, 2025

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma - GlobeNewswire

Apr 15, 2025

Apr 15, 2025

Breakthrough Cancer Treatment Gets FDA Special Status: 94% Success in Lymphoma Patients - Stock Titan

Apr 15, 2025

Apr 12, 2025

Prudential Financial Inc. Cuts Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

Apr 12, 2025

Apr 10, 2025

Lyell Immunopharma stock hits 52-week low at $0.4 By Investing.com - Investing.com South Africa

Apr 10, 2025

Apr 10, 2025

Lyell Immunopharma stock hits 52-week low at $0.4 - Investing.com

Apr 10, 2025

Apr 08, 2025

Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News

Apr 08, 2025

Apr 07, 2025

CAR-T developer Lyell lays off 73 ImmPact staffers, shutters LA facility shortly after acquisition - Fierce Pharma

Apr 07, 2025

Apr 02, 2025

Lyell Immunopharma stock hits 52-week low at $0.48 By Investing.com - Investing.com Canada

Apr 02, 2025

Apr 02, 2025

Lyell Immunopharma director Otis Brawley purchases shares for $19,958 By Investing.com - Investing.com India

Apr 02, 2025

Apr 02, 2025

Lyell Immunopharma director Otis Brawley purchases shares for $19,958 - Investing.com

Apr 02, 2025

Apr 02, 2025

Lyell Immunopharma stock hits 52-week low at $0.48 - Investing.com

Apr 02, 2025

Apr 01, 2025

Lyell Immunopharma’s LyFE Center Begins IMPT-314 Production - TipRanks

Apr 01, 2025

Apr 01, 2025

Lyell Immunopharma to close West Hills facility, cut 73 jobs - Investing.com

Apr 01, 2025

Apr 01, 2025

Lyell Immunopharma IncTo Close West Hills Manufacturing FacilitySEC Filing - MarketScreener

Apr 01, 2025

Mar 31, 2025

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Decline in Short Interest - MarketBeat

Mar 31, 2025

Mar 31, 2025

Charles Schwab Investment Management Inc. Has $1.05 Million Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World

Mar 31, 2025

Mar 28, 2025

Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey

Mar 28, 2025

Mar 27, 2025

Lyell Immunopharma Inc [LYEL] Director makes an insider purchase of 200,000 shares worth 0.12 million. - knoxdaily.com

Mar 27, 2025

Mar 26, 2025

Wednesday 3/26 Insider Buying Report: LYEL, LSAK - Nasdaq

Mar 26, 2025

Mar 25, 2025

Lyell Immunopharma director Ramachandra Sumant purchases $115,219 in stock - Investing.com

Mar 25, 2025

Mar 25, 2025

Lyell Immunopharma director Ramachandra Sumant purchases $115,219 in stock By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 23, 2025

Investor Interest in Lyell Immunopharma Stock (LYEL) Surges on Positive Analyst Report - markets.businessinsider.com

Mar 23, 2025